<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2219">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905238</url>
  </required_header>
  <id_info>
    <org_study_id>AOS-AD</org_study_id>
    <nct_id>NCT04905238</nct_id>
  </id_info>
  <brief_title>Obstructive Sleep Apnea Snd Biomarkers of Alzheimer's Disease</brief_title>
  <official_title>Pathophysiology Consequences of Obstructive Sleep Apnea in Biomarkers of Alzheimer's Disease. A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació d'investigació Sanitària de les Illes Balears</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació d'investigació Sanitària de les Illes Balears</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial on the effect of continuous positive pressure (CPAP). Objectives: 1) To&#xD;
      compare biomarkers of Alzheimer's disease in plasma samples from patients with Obstructive&#xD;
      sleep apnea (OSA) and without OSA. 2) To determine if CPAP reduces biomarkers of Alzheimer's&#xD;
      disease in plasma samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, parallel group, non-blinded, controlled clinical trial compared with conventional&#xD;
      treatment.&#xD;
&#xD;
      A. Protocol and intervention Patients with an Apnea-Hypopnea index (AHI)&gt;30 h-1 will be&#xD;
      assigned, using a 1:1 randomization table, to lifestyle recommendations treatment or to&#xD;
      lifestyle recommendations plus nasal CPAP, for a period of 4 months. CPAP pressure will be&#xD;
      titled with automatic using an AutoSet II device, ResMed.&#xD;
&#xD;
      B. Sample size For the estimation of the sample size, previous data were used (PLoS ONE&#xD;
      2019;14(9): e0221255). In this case, in order to compare the effect of CPAP it would be&#xD;
      necessary to randomize a total of 100 patients with OSA and 30 control subjects.&#xD;
&#xD;
      C. Ethical considerations&#xD;
&#xD;
        -  Indication of CPAP treatment for the prevention of Alzheimer's disease is not yet&#xD;
           accepted.&#xD;
&#xD;
        -  Those patients with an urgent study indication for the diagnosis and treatment of&#xD;
           respiratory sleep disorders (professional drivers, respiratory failure or risk&#xD;
           professions) will be excluded from the project. In the other cases, the delay in&#xD;
           healthcare for the performance of Polysomnography and CPAP titration exceeds the&#xD;
           duration of the study, therefore that patients assigned to the control arm (conventional&#xD;
           treatment) will not be exposed to a higher risk than the general population.&#xD;
&#xD;
      D. Methods.&#xD;
&#xD;
      . Polysomnography. It will be used as a screening test previous the randomization of the&#xD;
      included patients. The exploration and its interpretation will be carried out following the&#xD;
      recommendations of the American Academy of Sleep Medicine. Based on the results of this test,&#xD;
      only those patients with an AHI will continue in the study when AHI &gt;30 h-1. In these&#xD;
      patients the determinations listed below will be carried out immediately before randomization&#xD;
      (visit 1), at 4 weeks (visit 2), 16 weeks (visit 4) of allocation to the corresponding&#xD;
      treatment group&#xD;
&#xD;
        -  Clinical data: The medication used and other associated diseases already diagnosed will&#xD;
           be recorded.&#xD;
&#xD;
        -  Vital signs: recording of blood pressure, by means of a conventional triple taking, and&#xD;
           heart rate.&#xD;
&#xD;
        -  Anthropometric characteristics: age and weight in basal conditions, the perimeter of the&#xD;
           neck and waist / hip index will be measured. The lean mass index will be determined&#xD;
           using a Bodystat 1500 impedance system (Bodystat Ltd, United Kingdom).&#xD;
&#xD;
        -  Questionnaires: Epworth Sleepiness Scale, generic health-related quality of life (SF-12&#xD;
           and EuroQoL) and daily physical activity (International Physical Activity Questionnaire&#xD;
           or iPAQ).&#xD;
&#xD;
        -  Laboratory findings: blood count, coagulation, creatinine, serum sodium and potassium;&#xD;
           glycated hemoglobin (HbA1c) and blood glucose and insulin levels in fasting, from these&#xD;
           values will determine the resistance and sensitivity to insulin using the HOMA and&#xD;
           QUICKI indices; total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides;&#xD;
           and troponin I, homocysteine, NT-pro BNP and highly sensitive C-reactive protein.&#xD;
&#xD;
        -  Blood venous samples. 20 mL of venous blood will be collected, storing the plasma&#xD;
           obtained at -80 ºC for subsequent determination of β amiloid biomarkers (Aβ40, Aβ42, tau&#xD;
           y tau 181 (P-tau 181).&#xD;
&#xD;
        -  Night pulse oximetry. To assess the existence of residual nocturnal hypoxemia.&#xD;
&#xD;
        -  In the patients assigned to the CPAP treatment arm, a count of the hours of use of the&#xD;
           CPAP will be carried out at each visit by directly reading the automatic counter of each&#xD;
           equipment.&#xD;
&#xD;
      Statistic analysis The data will be expressed as mean ± standard deviation, median&#xD;
      (interquartile range) or percentage, depending on their type and distribution. For comparison&#xD;
      between groups Student's t-test, the U-Mann-Whitney or the chi-square test will be used, as&#xD;
      appropriate. The relations between variables will be analyzed using Pearson's correlation and&#xD;
      multiple linear regression analysis. The effect of treatment will be evaluated using general&#xD;
      linear models and repeated measures analysis of variance, with multiple comparisons post-hoc&#xD;
      using the Bonferroni test. A multiple logistic regression model will be applied to determine&#xD;
      the related variables with a response to treatment. Values of p &lt;0.05 will be considered&#xD;
      statistically significant. The statistical study will be performed with the SPSS program&#xD;
      version 22.0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Anticipated">May 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in β-amiloid 40 (Aβ-40) concentration</measure>
    <time_frame>4 months</time_frame>
    <description>To compare the change in Aβ-40 levels between the patients allocated to CPAP group and the control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>β-amiloid 40 (Aβ-40) concentration in OSA and in non-OSA patients</measure>
    <time_frame>Baseline</time_frame>
    <description>To compare Aβ-40 levels between OSA and non-OSA patients</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Continuous positive airway pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diet and general life style recommendations plus continuous positive airway pressure (CPAP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Diet and general life style recommendations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airway pressure</intervention_name>
    <description>Continuous positive airway pressure</description>
    <arm_group_label>Continuous positive airway pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cases: patients with AHI &gt; 30/h&#xD;
&#xD;
          -  Controls: subjects with AHI &lt; 5/h and Epworth &lt;10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Epworth&gt;18&#xD;
&#xD;
          -  BMI&lt;40Kg/M2&#xD;
&#xD;
          -  Arterial Hypertension&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Cerebrovascular disease&#xD;
&#xD;
          -  Ischemic heart disease&#xD;
&#xD;
          -  Cardiac arrhythmia&#xD;
&#xD;
          -  Chronic cardiovascular diseases&#xD;
&#xD;
          -  Daytime Oxygen saturation&gt;95%&#xD;
&#xD;
          -  Risk professions (professional drivers)&#xD;
&#xD;
          -  Concomitant treatment with antihypertensives, statins, antidiabetics, beta- blockers&#xD;
             or systemic corticosteroids.&#xD;
&#xD;
          -  Pretreatment with CPAP.&#xD;
&#xD;
          -  Participation in another clinical trial thirty days prior to randomization&#xD;
&#xD;
          -  Abnormal values of a cognitive test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma</city>
        <state>Balearic Islands</state>
        <zip>07006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma</city>
        <state>Balearic Islands</state>
        <zip>07006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep apnea obstructive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

